Seres Therapeutics (MCRB) Assets Average (2015 - 2026)
Seres Therapeutics (MCRB) posted Assets Average of $127.9 million for Q1 2026, down 9.18% sequentially from $140.8 million in Q4 2025, and down 15.85% YoY from $152.0 million in Q1 2025.
Seres Therapeutics (MCRB) Assets Average (2015 - 2026) Analysis & Trends
Seres Therapeutics has reported Assets Average for 12 years, with the latest figure at $127.9 million in Q1 2026.
- Quarterly Assets Average fell 15.85% year-over-year to $127.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.9 million (down 15.85% YoY) and the FY2025 annual result came in at $139.0 million, down 44.22% from the prior year.
- Assets Average slipped to $127.9 million in Q1 2026 per MCRB's latest filing, from $140.8 million in the prior quarter.
- Over five years, Assets Average peaked at $387.0 million in Q3 2023 and troughed at $127.9 million in Q1 2026.
- A 5-year average of $262.6 million and a median of $296.5 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average jumped 32.31% in 2023, then slumped 56.56% in 2025.
- Over 5 years, Assets Average stood at $330.3 million in 2022, then advanced by 9.94% to $363.1 million in 2023, then slumped by 56.14% to $159.3 million in 2024, then fell by 11.58% to $140.8 million in 2025, then dropped by 9.18% to $127.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $127.9 million, $140.8 million, and $143.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Seres Therapeutics | 44.07 Mn | 44.07 Mn | - | 109.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.60 Mn |
| Mar 31, 2026 | 127.91 Mn |
| Dec 31, 2025 | 140.83 Mn |
| Sep 30, 2025 | 143.64 Mn |
| Jun 30, 2025 | 153.99 Mn |
| Mar 31, 2025 | 152.00 Mn |
| Dec 31, 2024 | 159.28 Mn |
| Sep 30, 2024 | 250.24 Mn |
| Jun 30, 2024 | 331.50 Mn |
| Mar 31, 2024 | 349.93 Mn |
| Dec 31, 2023 | 363.15 Mn |
| Sep 30, 2023 | 387.04 Mn |
| Jun 30, 2023 | 338.29 Mn |
| Mar 31, 2023 | 309.49 Mn |
| Dec 31, 2022 | 330.33 Mn |
| Sep 30, 2022 | 292.53 Mn |
| Jun 30, 2022 | 296.54 Mn |
| Mar 31, 2022 | 337.37 Mn |
| Dec 31, 2021 | 375.58 Mn |
| Sep 30, 2021 | 332.97 Mn |